Return on Investment from the Prevention of Orphan Diseases in Kuwait


Spinal Muscular Atrophy
Inherited Retinal Disease
Premarital Screen
Preimplantation Genetic Diagnosis
In Vitro Fertilization

How to Cite

Abuhadida, S., Bastaki, L. ., Bash, B. ., & Alhindal, B. (2022). Return on Investment from the Prevention of Orphan Diseases in Kuwait. Annals of Public Health.


Spinal Muscular Atrophy type 1 and RPE65 mutation-associated Inherited Retinal dystrophy are two well-known Orphan diseases for expensive Orphan drugs. Being inheritable disorders, they can be prevented through a program that includes Premarital Genetic Screening to detect the defective gene carriers followed by Preimplantation Genetic Diagnosis to identify healthy gametes and In Vitro Fertilization. We developed a stochastic financial model to assess the Return on Investment over five years of implementing a prevention program to tackle these conditions from the financial perspective of the Ministry of Health in Kuwait. The ROI from the prevention program was shown to be highly cost-saving, with a probabilistic average of 9,710,311 USD (2,930,727 KWD). Every 1 USD or KWD spent on prevention would return 1.5 USD or KWD in savings. Meanwhile, not implementing the prevention program could cost the MOH a probabilistic average of 71,431,037 USD (21,555,325 KWD) within the same period. The findings of this study strongly support the adoption and implementation of the prevention program from the financial perspective of the MOH.


Useful information on rare diseases from an EU perspective. [Accessed 2022 Mar 12]. Available from:

Rare Disease Act of 2002, Pub. L. No. 107–280, 116 Stat. 1988 (2002). [Accessed 2022 Mar 12]. Available from:

Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet. 2008;372(9642):889–90.

Broekhoff TF, Sweegers CCG, Krijkamp EM, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG, et al. Early cost-effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 2021;24(6):759–69.

Ana S, Jimmy L. Rare Diseases, Diagnosis, Therapies, and Hope. St. Louis, MO: Rare Genomics Institute. 2014;6. [Accessed 2022 Mar 12]. Available from:

U.S. Food and Drug Administration. Package Insert-Zolgensma. [Accessed 2022 Mar 12]. Available from:

Al‐Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health Outcomes in spinal muscular atrophy type 1 following AVXS‐101 Gene Replacement therapy. Pediatr Pulmonol. 2018;54(2):179–85.

Johnson S, Buessing M, O’Connell T, Pitluck S, Ciulla TA. Cost-effectiveness of Voretigene Neparvovec-Rzyl vs standard care for RPE65-mediated inherited retinal disease. JAMA Ophthalmol. 2019;137(10):1115.

U.S. Food and Drug Administration. Package Insert-Luxturna. [Accessed 2022 Mar 12] Available from:

Verhaart IE, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis. 2017;12(1).

Sciorio R, Tramontano L, Catt J. Preimplantation Genetic diagnosis (PGD) and genetic testing for aneuploidy (PGT-A): Status and future challenges. Gynecol Endocrinol. 2019;36(1):6–11.

Ministry of Health in Kuwait. Kuwait Premarital Screening Program. [Accessed 2022 Mar 12]. Available from:

Kuwait times newspaper. 2019. [Accessed 2022 Mar 12]. Available from:

Cantoni E, Ronchetti E. A robust approach for skewed and heavy-tailed outcomes in the analysis of Health Care Expenditures. J Health Econ. 2006;25(2):198–213.

Hu C, Zhou H, Sharma A. Applying beta distribution in analyzing bounded outcome score data. AAPS J. 2020;22(3).

Kuwait Medical Genetic Center. [Accessed 2022 Mar 12]. Available from:

Basille C, Frydman R, Aly AE, Hesters L, Fanchin R, Tachdjian G, et al. Preimplantation Genetic diagnosis: State of the art. Eur J Obstet Gynecol Reprod Biol. 2009;145(1):9–13.

Bertram MY, Lauer JA, Stenberg K, Edejer TT. Methods for the economic evaluation of Health Care Interventions for priority setting in the health system: An update from WHO choice. Int J Health Policy Manag. 2021.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2022 Abuhadida S et al.